Verona Pharma to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Corporate Update Feb 18, 2021 02:00AM
CORRECTING and REPLACING -- Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD Feb 2, 2021 06:17AM
Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD Feb 2, 2021 02:00AM
Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19 Jan 14, 2021 02:00AM
Verona Pharma to Present at H.C. Wainwright Virtual BioConnect Conference Jan 5, 2021 02:00AM


Nov 9, 2020 02:00AM Verona Pharma Announces November 2020 Virtual Investor Conference Participation
Oct 29, 2020 03:00AM Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2020
Oct 22, 2020 02:00AM Verona Pharma to Announce Interim Results for the Three and Nine Months Ended September 30, 2020 and Provide Corporate Update
Oct 13, 2020 02:00AM Verona Pharma to Present Phase 2b COPD Symptom and Quality of Life Data with Ensifentrine at CHEST 2020
Sep 8, 2020 02:00AM Verona Pharma Initiates Pilot Study with pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19
Sep 2, 2020 02:00AM Verona Pharma to Present at H.C. Wainwright 22nd Annual Global Virtual Investment Conference
Aug 24, 2020 02:00AM Verona Pharma to Present Phase 2b data with Ensifentrine in COPD at the European Respiratory Society International Congress 2020
Aug 19, 2020 02:00AM Verona Pharma Initiates Multiple Dose Part of Phase 2 Clinical Trial with pMDI Formulation of Ensifentrine in COPD
Aug 14, 2020 02:00AM Verona Pharma plc Operational Update and Financial Results for the Three and Six Months Ended June 30, 2020
Aug 3, 2020 02:00AM Verona Pharma Announces August 2020 Virtual Investor Conference Participation
Jul 30, 2020 02:00AM Verona Pharma to Announce Interim Results for the Three and Six Months Ended June 30, 2020 and Provide Corporate Update
Jul 17, 2020 02:00AM Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription
May 14, 2020 02:00AM Verona Pharma Announces FDA Response to End-of-Phase 2 Briefing Package for Ensifentrine in COPD and Outlines Phase 3 ENHANCE Clinical Program
May 1, 2020 12:12PM Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at the American Thoracic Society 2020 International Conference
Apr 30, 2020 02:00AM Verona Pharma plc: Operational Update and Financial Results for the Three Months Ended March 31, 2020
Apr 23, 2020 02:00AM Verona Pharma to Announce Financial Results for the Three Months Ended March 31, 2020 and Provide Corporate Update
Apr 16, 2020 07:12AM Verona Pharma plc: Results of AGM
Mar 31, 2020 02:00AM Verona Pharma Reports Positive Efficacy and Safety Data with Single Dose pMDI Formulation of Ensifentrine in COPD
Mar 16, 2020 01:13PM 2019 Annual Report and Accounts and Notice of AGM
Feb 27, 2020 02:00AM Verona Pharma Reports Financial Results for the Full Year Ended December 31, 2019 and Provides Corporate Update
Feb 21, 2020 02:00AM Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update
Feb 14, 2020 02:00AM Verona Pharma Announces Publication of Key Phase 2b COPD Data in Respiratory Research
Feb 3, 2020 02:00AM Verona Pharma Announces Senior Management Changes
Feb 3, 2020 02:00AM Verona Pharma Announces Senior Management Changes
Jan 13, 2020 12:00AM Verona Pharma Reports Positive Top-line Data in 4 Week Phase 2b COPD Study with Nebulized Ensifentrine on Top of Tiotropium Therapy
Jan 10, 2020 06:00PM Verona Pharma to Report 4 Week Phase 2b COPD Dose-ranging Study Results with Nebulized Ensifentrine on Top of Tiotropium Therapy
Jan 7, 2020 02:00AM Verona Pharma Appoints David Moskowitz as Vice President, Capital Markets Strategy & Investor Relations
Nov 13, 2019 02:00AM Verona Pharma to Present at Jefferies 2019 London Healthcare Conference
Nov 11, 2019 02:00AM Verona Pharma to Participate in Two Upcoming Institutional Investor Conferences in New York
Oct 29, 2019 03:00AM Verona Pharma to Announce Financial Results for the Three and Nine Months Ended September 30, 2019 and Provide Clinical Development Update